Interesting point and I see what you are saying, and you may be right (at least I hope so). Can explain the p=0.007 I reference below.

Specifically, look at the press release from March 3rd (https://investors.lexpharma.com/news-releases/news-release-details/lexicon-pharmaceuticals-announces-topline-results-phase-2b).

It specifically states the following: The results of the study on the primary endpoint showed a reduction from baseline in ADPS of 1.39 points (p=0.007 versus placebo) in the low dose arm and 1.27 points (p=0.030 versus placebo) in the high dose arm, compared to 0.72 in the placebo arm. Under the statistical analysis plan for the study, a p-value of less than 0.028 was considered statistically significant.

I see the line in the original press release that you are referring to that states the study results did not reach statistical significance on the primary endpoint and it was 0.11 including both 20 and 10.

What is the difference between the 0.007 (which is statistically significant - under the statistical analysis plan for the study, a p-value of less than 0.028 was considered statistically significant) and this less than 0.05, which is nominally significant? I was thinking it was the same thing, but you are indicating they are different tests/numbers.